title: Reproducibility and reliability of anti-3-[¹⁸F]FACBC uptake measurements in background structures and malignant lesions on follow-up PET-CT in prostate carcinoma: an exploratory analysis.
abstract: OBJECTIVE
  The aim of this study is to examine the reproducibility of anti-1-amino-3-[(18)F]fluorocyclobutane-1-carboxylic acid (anti-3-[(18)F]FACBC) quantitative measurements in key background structures and untreated malignant lesions.
  
  
  METHODS
  Retrospective review of 14 patients who underwent follow-up anti-3-[(18)F]FACBC positron emission tomography-X-ray computed tomography (PET-CT) for prostate carcinoma recurrence. Standard uptake values (SUV) were measured in both original and follow-up scans in key background structures and untreated malignant lesions. Absolute and percent mean difference in SUV between scans and interclass correlation coefficients (ICC) were also computed.
  
  
  RESULTS
  Mean (±SD, range) scan interval was 17.4 months (±7.1, 4-29). %Mean difference in SUVmean was <20 % in background structures with low absolute differences. ICCs were >0.6 except for early-phase blood pool (ICC = 0.4). SUVmax in malignant lesions without interim therapy increased or remained stable over time.
  
  
  CONCLUSIONS
  Despite variable time interval between scans, FACBC PET-CT demonstrates acceptable reproducibility in key background structures. Untreated malignant lesions showed stable or increased uptake over time. A formal test-retest study is planned.
authors.affiliation: Division of Nuclear Medicine and Molecular Imaging, Department of Radiology and Imaging Sciences, Emory University Hospital, Room E152, 1364 Clifton Road, Atlanta, GA, 30322, USA.
authors.forename: Oluwaseun A
authors.initials: OA
authors.lastname: Odewole
authors.forename: Oyeladun A
authors.initials: OA
authors.lastname: Oyenuga
authors.forename: Funmilayo
authors.initials: F
authors.lastname: Tade
authors.forename: Bital
authors.initials: B
authors.lastname: Savir-Baruch
authors.forename: Peter T
authors.initials: PT
authors.lastname: Nieh
authors.forename: Viraj
authors.initials: V
authors.lastname: Master
authors.forename: Zhengjia
authors.initials: Z
authors.lastname: Chen
authors.forename: Xiaojing
authors.initials: X
authors.lastname: Wang
authors.forename: Ashesh B
authors.initials: AB
authors.lastname: Jani
authors.forename: Leah M
authors.initials: LM
authors.lastname: Bellamy
authors.forename: Raghuveer K
authors.initials: RK
authors.lastname: Halkar
authors.forename: Mark M
authors.initials: MM
authors.lastname: Goodman
authors.forename: David M
authors.initials: DM
authors.lastname: Schuster
mesh_terms: D000368:Aged; D002264:Carboxylic Acids / Q000493:pharmacokinetics*; D003503:Cyclobutanes / Q000493:pharmacokinetics*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging*; D015203:Reproducibility of Results; D014057:Tomography, X-Ray Computed
chemical_list: D002264:Carboxylic Acids; D003503:Cyclobutanes; C117460:fluciclovine F-18